Fore Biotherapeutics Presents Positive Interim Data From Phase 1/2a Trial Evaluating FORE8394 in Patients With Advanced Tumors With Activating BRAF Alterations at ESMO 2022
Fore Biotherapeutics (Fore Bio), a precision oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients, announced the presentation of new data demonstrating that FORE8394, a next-generation BRAF inhibitor, provides evidence of durable anti-tumor activity and patient benefit in BRAF-mutated (V600+) cancers. Data from the ongoing Phase 1/2a study evaluating FORE8394 for the treatment of advanced solid and central nervous system (CNS) tumors with activating BRAF alterations were presented in a poster session at the European Society of Medical Oncology Congress (ESMO) taking place in Paris, France.
“I am extremely proud of the progress this team has made in advancing our next-generation, and potential best-in-class BRAF-inhibitor to address the limitations of the current standards of care and improve outcomes for patients with cancer,” said Matthew Ros, Chief Executive Officer of Fore Biotherapeutics. "These results are very encouraging and reinforce our conviction that FORE8394 has the potential to provide meaningful benefit to patients with BRAF-mutated cancers with high unmet need. We are embarking upon developing this novel treatment and are on track to initiate our global Phase 2 trial next quarter.”
As of the data cutoff date of July 31, 2022, 108 adults and children have received ≥1 dose of FORE8394 and are included in the safety population; 51 adults (≥18 years) met the criteria for the V600+ efficacy analysis; overall response rate (ORR) was 25.5% and median duration of response: 17.8 months. An additional analysis was conducted in the MAPK-inhibitor naïve subset, excluding patients with colorectal cancer (CRC) (N=21). Patients received 900-3600 mg/day of oral FORE8394 alone or with cobicistat (CYP3A4 inhibitor) to increase exposure, with the majority having been treated with total daily doses of 900-1800 mg.
Key Findings from the Ongoing Phase 1/2a Study
In MAPK inhibitor-naïve adult V600+ patients (N=21, excluding CRC), confirmed responses and durable benefit was seen across multiple tumor types
Clinical activity observed in this population includes ORR= 42.9%, clinical benefit rate ≥ 24 weeks= 71.4%, median duration of response was 17.8 months and median progression free survival (PFS) was 28.6 months
- In patients with primary CNS tumors, 4 of 4 patients with high grade glioma and 2 of 3 patients with low grade glioma experienced a partial response (PR) ; 1 had stable disease and remains on treatment after 15+ months
- Of 6 patients with papillary thyroid cancer, median PFS was not reached (median follow-up 5.6 years)
- Clinical activity observed in this population includes ORR= 42.9%, clinical benefit rate ≥ 24 weeks= 71.4%, median duration of response was 17.8 months and median progression free survival (PFS) was 28.6 months
- Additional responses were observed in patients with V600+ ovarian cancer where 3 of 3 patients had PR; 2 having received prior MAPK-targeted treatments
FORE8394 demonstrated a favorable safety profile, with long-term tolerability, across the 108 patients
- Adverse events were transient and manageable
- Symptomatic adverse events (AEs) were low grade (Grade 1 or 2), mild and included fatigue, nausea, diarrhea & vomiting
- Hepatic laboratory changes were manageable with dose interruption or modification
- No secondary cutaneous skin malignancies or acanthomas occurred
- Only 1 participant discontinued treatment due to treatment related adverse event
"In this heterogeneous and heavily pre-treated patient population, the overall response rate and meaningful durations of response demonstrates the potential of FORE8394 to uniquely target tumors with BRAF alterations," said Stacie Shepherd, MD, PhD, Chief Medical Officer of Fore Biotherapeutics. "We're excited that the majority of gliomas demonstrated response and the prolonged benefit and tolerability experienced by some patients receiving FORE8394. Based on the strength of these findings, our Phase 2 study will further evaluate FORE8394 in patients with both solid and CNS tumors with BRAF fusions and recurrent primary CNS tumors with BRAF V600E mutations.”
“There are several limitations with first-generation BRAF inhibitors, including treatment resistance leading to disease progression and the paradoxical activation of the MAPK pathway, leading to secondary cutaneous skin cancers. In addition, these agents are inactive against class II BRAF alteration,” said Eric Sherman, MD, principal investigator and medical oncologist, Memorial Sloan Kettering Cancer Center. “These results suggest FORE8394 may provide meaningful benefit to patients, and we look forward to further exploring its potential in the upcoming Phase 2 study.”
FORE8394 is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF. It was designed to target a wide range of BRAF mutations while sparing wild-type forms of RAF. Preclinical studies and clinical trials have shown that its unique mechanism of action effectively inhibits not only the constitutively active BRAFV600 monomers targeted by first-generation RAF inhibitors but also disrupts constitutively active dimeric BRAF class II mutants, fusions, splice variants and others. Unlike first-generation RAF inhibitors, FORE8394 does not induce paradoxical activation of the RAF/MEK/ERK pathway. As a “paradox breaker,” FORE8394 could therefore treat acquired resistance to current RAF inhibitors and, more generally, yield improved safety and more durable efficacy than first-generation RAF inhibitors.
About Fore Biotherapeutics
Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients. Its lead asset FORE8394 is a Class I/II BRAF inhibitor with demonstrated clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. Leveraging a proprietary functional genomics platform that can screen a wide range of known mutations for cancer-driving genes, the Fore R&D team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options. For more information, please visit www.fore.bio or follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Investors and Media:
212.600.1902 | ForeBio@argotpartners.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Capitolis to Present at TradeTech FX 202227.9.2022 20:10:00 CEST | Press release
Capitolis, the technology company reimagining financial markets, will join TradeTech FX, the largest buy side FX event in Europe. This is the first year Capitolis will have a presence on the ground at the event. Ben Tobin, Capitolis SVP, Head of Europe/Portfolio Optimization, will join a panel of FX industry leaders on Wednesday, 9/27, at 12:55 local time to discuss how uncleared margin rules (UMR) and the Standardized Approach for Counterparty Credit Risk (SA-CCR) have impacted the FX trading desk and market structure – and share predictions for how it could influence other FX products in the future. “We’ve been a partner and provider of optimization services to banks, hedge funds, and real money managers over the past five years,” said Ben Tobin, Capitolis SVP, Head of Europe/Portfolio Optimization. “We’ve already helped our customers reduce trillions of notional since the beginning of 2022, including optimization between the banks and their diverse client base.” TradeTech FX attende
Fintatech Announces Trading Chart Designer 2.027.9.2022 18:32:00 CEST | Press release
Fintatech, a custom trading software development company and provider of high-performance capital market solutions with a universal 'trading platform skeleton' in its core that is supplemented by interconnective module-based software components according to the client’s requirements, announces significant enhancements to their Trading Chart Designer software solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220927005640/en/ Fintatech Trading Chart Designer 2.0 Release (Graphic: Business Wire) Our current trading software solutions list is comprised of: - Trading Chart Designer - Trading Platform Designer - Trading Data Server Read on to learn more about our enhancements in Trading Chart Designer 2.0, including: New indicators Traders may use over 130 Technical Analysis Indicators on our platform to do the finest market analysis. We keep researching and adding new indicators, so that traders may make even more precise
Globee® Awards Issues Call for Business Awards Nominations From All Over The World27.9.2022 17:00:00 CEST | Press release
The Globee® Awards, organizer of the world’s premier business awards programs and business ranking lists, is now accepting nominations for the Annual Business Excellence Awards from all over the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220927005179/en/ Learn more about the Globee Business Awards and how to nominate here: https://globeeawards.com/business-awards/. The coveted annual Globee® Business Excellence Awards program recognizes and honors the world’s best in organizational performance, products and services, innovations, executives and management teams, women in business and the professions, case studies and successful deployments, communications, public relations and marketing campaigns, product management, websites, blogs, white-papers, videos, advertisements, creativity, partner programs, and customer satisfaction programs from every major industry in the world. Individuals and organizations from anywh
Recurly Enhances Revenue Recognition Solution, Helping Subscription Businesses Automate Complex Accounting Processes27.9.2022 16:00:00 CEST | Press release
Recurly, Inc., a leading subscription management and billing platform for high-growth brands, has announced an agreement to acquire LeapRev, a global revenue recognition and forecasting solution. This acquisition will create a single source for subscription management, recurring billing, and revenue management that empowers Recurly customers to better focus on driving growth among increasingly complex and evolving revenue accounting and reporting standards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220927005356/en/ Recurly launches enhanced revenue recognition capabilities. (Graphic: Business Wire) “Recurly powers recurring billing management for many of the world’s leading brands. Part of our customers’ success has resulted from Recurly’s ability to support more granular, pay-as-you-go pricing models. This trend toward enabling greater flexibility in pricing models creates a greater need for accounting automation,” sai
Andersen Global Cultivates Additional Presence in East Asia with Law Firm of Lee & Ko27.9.2022 15:30:00 CEST | Press release
Andersen Global strengthens its global presence in East Asia through a non-exclusive Collaboration Agreement with the full-service law firm Lee & Ko, extending the global organization’s reach into South Korea. Founded in 1977, Lee & Ko is one of the oldest firms in South Korea with more than 800 professionals and 300 Partners. The firm provides clients with full service across its eight major practice groups: antitrust and competition, banking and finance, corporate and M&A, intellectual property, labor and employment, litigation and arbitration, tax and customs, and white-collar crimes. Lee & Ko is consistently recognized as a Tier 1 firm by organizations, including Asialaw, IFLR1000, Legal 500 Asia-Pacific, Chambers & Partners Asia-Pacific, among others. “Throughout our firm’s history, we’ve grown to be widely recognized as a leading firm that provides clients with best-in-class service and comprehensive legal coverage,” Senior Partner Hyeong Gun Lee said. “As a collaborating firm of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom